A gyomor-és gyomor-nyelőcső átmenet (GEJ) rák molekuláris diagnosztikája

Knowledge base

Molecular diagnostics of gastric cancer and gastroesophageal junction adenocarcinoma

In advanced or metastatic HER-2 positive gastric cancer, targeted treatment with HER-2 inhibitor therapy is possible. 

Approximately 10% of gastric cancers are of the type where HER2 gene amplification can be detected.

In the case of EGFR, the gene is also amplified, causing about 5% of gastric cancers, and point mutations of the gene can also occur in 3-5% of cases. In both cases, the use of EGFR inhibitor treatments is typical.

In 15% of gastric cancers, the MET gene is multiplied, and in these cases, targeted inhibition of the increased protein is the basis of targeted treatment.

Mutations in the BRAF gene may also occur in 1% of gastric cancers, in which case treatment with existing BRAF inhibitors is recommended.

ASCO Breakthrough Innovations in Oncology

2019 Read more

About us

Our story

2003— —2022

Oncompass Medicine is a Hungarian medical enterprise dealing with the development of decision support and diagnostic medical devices that help the personalized treatment of cancer patients. 

More information